Medical data for sale?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
26 minutes ago
- CTV News
N.B. health network says hospitals overcrowded
Atlantic Watch Horizon Health received permission to discharge some patients in N.B. hospitals to free up space.
Globe and Mail
26 minutes ago
- Globe and Mail
Obesity Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Othe besity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In July 2025, Carmot Therapeutics Inc. announced a study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM). In July 2025, Innovent Biologics (Suzhou) Co. Ltd. conducted a study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study. In July 2025, Zealand Pharma organized a study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability. Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management. In July 2025, Eli Lilly and Company conducted a study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits. In July 2025, Rhythm Pharmaceuticals Inc. organized a Phase 3 Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CTV News
an hour ago
- CTV News
N.B. grants Horizon Health 30 days for nursing home placement prioritization
New Brunswick's Department of Social Development has granted Horizon Health Network 'critical state admission prioritization status.' The move means patients with no medical need for care at four regional hospitals will be bumped to the top of the list for long-term care beds for the next 30 days. Alternate Level of Care (ALC) patients at the Dr. Everett Chalmers Hospital in Fredericton, the Saint John Regional Hospital, the Upper River Valley Hospital in Waterville, and the Miramichi Regional Hospital will be bumped up to the top of the wait list for available beds in long-term care (LTC). According to Horizon, there are over 650 patients at their hospitals who do not need acute care but cannot be discharged as they are waiting for beds elsewhere. If more beds were readily available, the health agency says more then half of those patients would immediately be out the door. Around 40 per cent of acute care beds in Horizon facilities are take by people who have no medical reason to still be at the hospital. 'We do not want anyone to think that they are not a priority,' Social Development Minister Cindy Miles told reporters Wednesday. 'We will do all we can to support this process and moving forward as quickly as we can in the areas that we've identified, and the folks in community, we will do all we can to make sure that you're getting the support and the services that you need.' According to Social Development, nursing home admissions are normally done chronologically. Speaking with reporters Wednesday, Horizon Health Network President and CEO Margaret Melanson was pleased to hear the request was granted in a timely matter. After the initial 30 days, she says the need for prioritization status will be evaluated. 'This number is occurring in July, when we would typically see numbers peak more traditionally during the fall period,' Melanson notes. 'Therefore, in order to prepare adequately for bed availability during a flu season, for example, we needed to act now with this particular emergency order to ensure that we would have hopefully some bed capacity in planning for the fall period.' Melanson is hopeful to move around 20 people out of both the Saint John and Fredericton Hospitals, and a little less for the other two centres. The goal would still leave hundreds waiting in hospital, but officials note there are just not enough LTC beds available. To solve the issue long-term, Melanson says she will continue to collaborate with both social development and the health department. 'When we have admitted patients who are needing to be cared for in a hallway, a dining room and other nontraditional spaces, I believe we can all agree that this is not high quality care.' Speaking to CTV Atlantic ahead of the province decision, New Brunswick Nurses Union President Paula Doucet was pleased to see Horizon make the request. She says nurses are continuing to battle working in overcrowded conditions and having to treat patients outside of a typical hospital room. Doucet adds whatever decision is made to address the issue long term, all parties need to be at the table. 'It's really difficult to come up with an answer that's going to solve every problem, especially when we're in a crisis,' she says. 'But obviously involving the input from the frontline staff, multiple stakeholders and all of those different departments, I think will go a long way.' For more New Brunswick news, visit our dedicated provincial page.
